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Abstract 
Peptidomimetics are a broad family of compounds designed to mimic the main structural features of 
peptides, avoiding their metabolic drawbacks. In particular, universal peptidomimetics  use only peptide 
side-chain analogs to mimic different secondary structures. In this work, a novel method is proposed to 
identify universal peptidomimetics. It is based on a single Meta-Dynamics simulation which allows the 
reconstruction of the Free Energy Surface of the compound of interest. Subsequently, cluster analysis is 
carried out to obtain representative structures. Such conformers are then compared to ideal secondary 
structures to assess their mimicking ability. This protocol was validated against known universal 
peptidomimetics. 
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Introduction 
Peptides are an important family of  molecules, having an essential role in numerous biological processes, 
ranging from cell signaling  to immune response. Accordingly, they are thoroughly investigated as potential 
bioactive agents [1-4].  Natural peptides are generally not considered as optimal drug candidates by the 
medicinal chemistry community [5], because of their limited stability toward proteolysis and the generally 
poor transport properties across body barriers. Moreover,  their inherent flexibility enables interaction with 
multiple receptors besides the desired target, increasing the risk of undesired side effects [6]. Thus, it is 
expedient to design small peptide-like chains encompassing their pharmacophore  while improving their 
pharmacokinetic and pharmacodynamic properties.  Such molecules are called “peptidomimetics” [7]. 
Peptidomimetics have been broadly studied  at theoretical and experimental level [8-10]. 
Many peptidomimetics closely resemble peptides, mimicking both backbone and side chains. Usually, they 
are actually peptides containing modified, non-natural residues  to constrain their structure in the relevant 
active conformations, e.g.  by applying peripheral groups [11,12] or by making a cyclic peptide [13,14]. 
Another interesting type of peptidomimetics are compounds that achieve mimicry using only side chains 
analogs. The first example of this type of compounds are the β turn mimics by Hirschmann and Smith [15-
17]. This type of peptidomimetics were thoroughly studied by several authors [18-23], and has been  
defined  as minimalist peptidomimetics [18]. Even though minimalist peptidomimetics only mimic peptide 
side chains, they have the potential to mimic hot-spots residues at protein-protein interfaces [24-26], since 
side chain substituents account for about 80% of the interactions [27-29].  
Minimalist peptidomimetics should be synthetically accessible with different side chains, should display 
thermodynamically and kinetically accessible conformations for induced fit and finally side chains 
orientation should depend on a limited number of significant degrees of freedom [18]. 
Recently, a subset of the minimalist peptidomimetics family, comprising molecules that are flexible enough 
to mimic different kinds of secondary structures, has been identified [18]. These compounds have been 
labeled universal peptidomimetics. Burgess and coworkers also developed a protocol to evaluate the 
performance of a compound as a potential universal peptidomimetic [21]. This protocol is based on Density 
Functional Theory (DFT) calculations to evaluate the energy barriers between relevant conformations, and 
on Quenched Molecular Dynamics (QMD) and cluster analysis  to explore the conformational ensemble of 
the molecules. 
In this work we propose an alternative method to identify universal peptidomimetics based on  
MetaDynamics (MetaD) [30-32] and cluster analysis. MetaD is an enhanced sampling technique based on 
phase space coarse graining through the identification of collective variables describing the system that 
allows the reconstruction of  its free energy surface [33-37]. In particular, Well-Tempered MetaD 
(WTMetaD) [38] has been employed  to explore the conformational space of the investigated compounds  
and to estimate the energy barriers between the most populated conformers, whereas subsequent cluster 
analysis  has been  used to identify representative conformations from the Free Energy Surfaces (FESs) 
minima . To evaluate the ability of the studied compounds to mimic typical secondary structure elements, 
the Cα-Cβ vectors (as defined in Figure 1) of the relevant conformations were  overlaid on the corresponding 
atoms  of ideal secondary structures. Our protocol requires just one production phase simulation for every 
tested compound and  provides thermodynamically relevant conformations that effectively mimic 
secondary structures elements. To validate our protocol, we tested it on two universal peptidomimetc  
scaffolds proposed and previously studied by Ko et al.   We investigated their conformational and energetic 
properties, considering the effect of the scaffold structure and sidechains variability, defining which 
secondary structure elements are better reproduced. Our results, coherent with previous observations, 
assess the viability of the proposed protocol as a validation tool for universal peptidomimetics.  
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Materials and Methods 
 
Figure 1: (a): peptidomimetic scaffolds that were considered; Cα atoms in blue, Cβ 
atoms in red, and in green, the degrees of freedom used as CVs for the WT-MetaD 
simulation. (b): On the left, structure and nomenclature of the amino acid side 
chains that were considered. On the right, side chain combinations that were used 
to construct the peptidomimetic molecules for both scaffolds 1 and 2. 
 
(For interpretation of the references to color in the figure legends, the reader is 
referred to the digital version of this article). 
 
 
The peptidomimetic scaffolds considered in this work are presented in Figure 1 Panel (a). Scaffold 1 is 
based on a 1,3,4 - oxadiazole, whereas Scaffold 2 is based on a 1,2,3 - triazole. These two scaffolds were 
proposed by Ko et al. [18] as universal peptidomimetics. In particular Scaffold 1 was also synthesized with a 
variety of side chains, reported in Figure 1 Panel (b). We simulated compounds based on Scaffold 1 and 2 
with the combinations of side chains R1 and R2 reported in Figure 1 Panel (b).  
In order to investigate the steric hindrance and charge effects of substituents R1 and R2 we tested, as 
limiting cases, scaffolds 1 and 2 with side chains of Alanine and Tryptophan or Arginine and Aspartic Acid 
respectively. 
Therefore, we considered twenty-one side chain combinations, and two scaffolds, amounting to forty-two 
molecules Figure 1 Panel (b). We will henceforth reference to these compounds  with the following 
nomenclature: NR1R2, where N is the number of the Scaffold, and R1, R2 are letters, identical to the one-
letter codes of the amino acids.(i.e. 1YE is the compound based on Scaffold 1, with R1 and R2 the side chains 
of Tyrosine and Glutamic Acid respectively).  
The molecules were initially optimized with Gaussian 09 (Revision D.01) [39] using Restricted Hartree-Fock 
(RHF) with basis set 6-31G(d). Each optimized structure has been solvated in a cubic box of 4 nm with TIP3P 
water. Every system has been submitted to geometry optimization with the steepest descent algorithm 
with a convergence of 100 kJ mol-1 nm-1. Then we performed a 1 ns NVT equilibration at 300 K, using 
velocity rescaling as temperature coupling algorithm and τT = 0.01 ps. A 1 ns NPT equilibration followed, 
using the Berendsen pressure coupling algorithm with isotropic coupling, a reference pressure of 1 bar, τP = 
2 ps, and the reference isothermal compressibility of water: 4.5 × 10-5 bar-1. 
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After the equilibration phases, we ran a 50 ns WTMetaD simulation with a 20.0 kJ mol-1 bias-factor, at a 
reference temperature of 300 K. The φ and ψ torsion angles (defined in Figure 1 Panel (a)) have been used 
as Collective Variables (CVs), because they describe the relative orientation of the side chains. A Gaussian 
hill with σ = 0.1 rad for both φ and ψ and an initial height of 0.5 kJ mol-1 was added once every 100 steps. 
The simulation was sped up by saving the Gaussian hills on a grid that ranged from -π to +π rad and spaced 
0.025 rad in the directions of both CVs. 
The molecules have been described using the Generalized Amber Force Field (GAFF) [40,41]. MD 
simulations were performed using the leap-frog algorithm with 2 fs time-step, with holonomic constraints 
on every bond enforced using the LINCS algorithm. Simulations and subsequent analysis were performed 
with the GROMACS 5.0.4 [42,43] program suite along with PLUMED version 2.2.2 [44]. 
Cluster analysis were performed with the GROMOS [45] algorithm. 
The reference ideal secondary structures were obtained from ProBuilder On-line, a service based on VEGA 
[46]. 
Results and Discussion 
We calculated the FES for each molecule in Figure 1. In general, the FES exhibits four distinct minima 
corresponding to different conformations, separated by low free energy barriers. As an example, FES of 
molecule 1AA is shown in Figure 2 Panel (a) (FES of all other molecules are reported in Supporting 
Informations). This is in good agreement with the definition of minimalist mimics: the preferred 
conformation should be rather independent on the different type of side chains of the compound. 
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Figure 2: (a): FES / kJ mol
-1
 of molecule 1AA, projected in the two CVs φ and ψ; in evidence, the cluster centers of 
the four basins. (b): Box plots of the populations of the four basins, showing the distribution of the population 
among all side chains, for both scaffolds. 
 
While the general shape of the FES is the same for every molecule, the depth 
and width of each basin differ among the different molecules. 
First of all, we analyzed the influence of the scaffold on the population of each of the four basins (Figure 2 
Panel (b)). The population of each basin is defined accordingly to Equation 1. 
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Equation 1 
 
 
Where   is a basin,   is the total number of basins (four in this case), and    is the Free energy of point   in 
basin  . 
From Figure 2 Panel (b) we notice that there are significant differences in the population of the four basins 
depending on the scaffold type. In particular, scaffold 1 preferentially populates basin one, whereas basin 4 
is preferentially populated by scaffold 2. Additionally, the third basin is similarly occupied by the two 
scaffolds. Moreover, a slight preference for the third basin over the second is observed. These observations 
suggest that one scaffold will better mimic a secondary structure whose  Cα-Cβ vectors have the 
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characteristic orientation of a particular basin. Within each basin, the side chains influence which 
conformation is preferred. 
The representative structures of the four basins were obtained performing cluster analysis with GROMOS 
algorithm [45], using 0.1 nm RMSD cutoff. Structures were clustered based on Cα and Cβ atoms, highlighted 
in Figure 1 Panel (a). 
We obtained a single cluster for each basin, and the central molecule was chosen as representative for the 
whole basin. We tested the ability of the aforementioned central structures to mimic ideal secondary 
structures, as our aim was to highlight the difference between the two scaffolds and among the side chains. 
To this purpose we calculated the RMSD between central structure and ideal secondary structures 
superimposing the Cα and Cβ atoms 
To evaluate the quality of an overlay, we adopted the same criterion employed by Burgess and coworkers: 
from 0.03 to 0.05 nm “very good”, from 0.05 to 0.07 nm “good”, from 0.07 to 0.11 “poor” and greater than 
0.11 “bad”. 
 
Figure 3: RMSD of Cα-Cβ vectors of the four basins for all the side chain combinations 
for both scaffolds with the peptide sequence α helix i-i+3. The green, purple and gray lines 
highlight RMSD values of 0.05, 0.07 and 0.11 nm. 
 
At first, we assessed the effect of side chains on the superimposition quality between peptidomimetics and 
an archetypical  α helical secondary structure. In particular we evaluated the overlay between the side 
chains of our peptidomimetics and the side chains of the i-i+3 residues of the ideal α helix (Figure 3).  
From now on, we will refer to specific pairs of amino acid belonging to an ideal secondary structure using 
the nomenclature “i-i+n” where n is an integer ≥ 1 indicating the reciprocal positions along the sequence. 
In Figure 3 the green, purple and dark gray lines mark the values of RMSD that act as boundaries between 
two overlay quality ranges. As an example, an RMSD value between the purple and the dark gray line 
manifests “poor” overlay, and an RMSD value under the green line stands for “very good” overlay. 
RMSD values have a greater central tendency for structures of basin 1 than for structures of the other 
basins. The secondary structure α helix i-i+3 is better mimicked by structures in basins 1 and 4, for both 
scaffolds, independently from the side chains. Analogously, no significant side chain dependence of the 
overlay quality was observed for any other secondary structure (data not shown). 
These results support the hypotheses that scaffolds 1 and 2 are universal peptidomimetics, as previously 
inferred by Ko et. al. 
Since the different side chains do not significantly affect the ability of our scaffolds to mimic a secondary 
structure, from now on we will focus our analysis on the simplest molecules (1AA and 2AA), to evaluate 
their peptidomimetic quality, by overlaying them on various ideal secondary structures (Figure 4). 
On the whole, we observe that both scaffolds are able to mimic many different secondary structures, as 
expected for universal peptidomimetics. We recognize that our scaffolds are suited to mimic various kinds 
of turns. In particular,  basins 1 and 4 are very good at mimicking β turn i-i+2, while basins 2 and 3 can 
mimic very well the inverse β turn i+1-i+2. 
Concerning α helices, secondary structures from i-i+2 to i-i+4 are well mimicked by both scaffolds. 
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Finally, our scaffolds are able to mimic β strands i-i+1 and i-i+2 with a good RMSD. 
Our protocol allowed us not only to evaluate the geometric similarities between peptidomimetics and 
peptide sequences, but also to correlate this information with the population of the different conformers. 
In Figure 5 Panel (a) we plotted the RMSD values for the overlays of molecules 1AA and 2AA with all the 
secondary structures against the population of the four basins of the molecules (we made separate plots 
for the secondary structures of the helix family and of the strand - turn families). This analysis points out 
that many peptidomimetics which overlay with at least “good” RMSD values also display a significant 
population. Actually, we noticed that a few structures share  two of the important characteristics of a 
promising peptidomimetic: they have both a “very good” RMSD  (with respect to a certain secondary 
structure) and they are also highly populated (≥ 0.25). These structures are reported in Figure 5 Panel (b). 
Structures highlighted in this table are the most promising to mimic the corresponding secondary 
structures.  
As an example, Figure 6 Panel (a) shows the overlay between molecule 2AA basin 3 and α helix i-i+2, 
whereas Figure 6 Panel (b) shows the overlay between basin 1 of molecule 1AA and secondary structure i-
i+2 of an ideal β turn.  
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Figure 4: RMSD of Cα-Cβ vectors of the four basins of molecules 1AA and 2AA with 
the secondary structures of the helices family (a) and of the strand and turn families (b) 
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Figure 5: (a): RMSD of vectors of Cα-Cβ the four basins of molecules 1AA and 2AA with various secondary structures compared to 
the population of the basin of each structure. (b): Overlays with RMSD values ≤ 0.05 nm and basin population ≥ 0.25 
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Figure 6: (a):  Central structure of basin 3 of molecule 2AA(orange) overlaid on the secondary structure α helix i-i+2 
(blue). (b): Central structure of basin 1 of molecule 1AA (orange) overlaid on the secondary structure β turn i-i+2. 
Backbones are depicted with sticks, Cα and Cβ atoms are highlighted with spheres. 
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Conclusions 
In this work we developed a new protocol to evaluate the ability of different classes of molecules to act as 
universal peptitomimetics. A WTMetaD simulation allowed us to investigate the conformational space 
relative to the chosen collective variables for every molecule. An approach based on cluster analysis was 
developed to extract structures from the dynamics that are representative of the FES minima and suitable 
for further analysis. Those conformers were overlaid with ideal secondary structures, confirming that 
scaffolds 1 and 2 are suitable to mimic them, with a clear propensity for short sequences in helices and 
turns. The ability of molecules to mimic secondary structures is independent on the side chains. Finally, we 
correlated the  mimicking ability of our compounds with the populations of basins, pointing out high 
populated structures exhibiting  a very good overlay with ideal secondary structures.  
This protocol allows to investigate the peptidomimetic character of a molecule using a single WTMetaD 
simulation.  
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